VaccinesA more detailed look at Moderna’s messenger RNA vaccine is expected to appear in a peer-reviewed journal soon, which may answer some lingering questions over the level of antibodies that the vaccine produced.
A final-stage study of Moderna’s vaccine in 30,000 people is set to begin this month. Investors will also be looking for results in July from a vaccine AstraZeneca is developing with Oxford University.Investors may also get a first look at a messenger RNA product from BioNTech and Pfizer sometime in the third quarter.
The companies are simultaneously developing four different vaccine candidates and one could enter the final stage of testing later this summer.Johnson & Johnson will start the first stage of testing of its.